9/12/2013

Gilead Sciences filed an application with the FDA for approval to market its oral drug idelalisib for treatment of patients with indolent non-Hodgkin lymphoma who don't respond to Rituxan and chemotherapy with an alkylating-agent. A similar application is being prepared for Europe.

Related Summaries